<!DOCTYPE html>
<html id="b5b8ca79a5e0407486042fae35b5d861:96388957" data-origid="96388957" class="anndoc" data-anndoc-version="2.0" lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="UTF-8"/>
		<meta name="generator" content="org.rostlab.relna"/>
		<title>b5b8ca79a5e0407486042fae35b5d861:96388957</title>
	</head>
	<body>
		<article>
			<section data-type="title">
				<h2 id="s1h1">Retinoid differentiation therapy in promyelocytic leukemia.</h2>
			</section>
			<section data-type="abstract">
				<h3 id="s2h1">Abstract</h3>
				<div class="content">
					<p id = "s2p1">Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia characterized by the morphology of the blast cells, a specific t (15; 17) translocation, and risks of definite coagulopathy. Recently this leukemia was further characterized by an exquisite sensitivity to all-trans retinoic acid 's differentiation effect and the production of a fusion gene altering the gene of RARalpha and a novel gene PML. In vivo differentiation therapy with retinoids in APL patients follows strict guidelines related both to the APL cell and the biodisposal of all-trans retinoic acid.</p>
				</div>
			</section>
		</article>
	</body>
</html>